Slide background
TAmiRNA – Triple A research and development of RNA diagnostics and therapeutics
Slide background
TAmiRNA – Introducing personalized medicine to Aging
Slide background
TAmiRNA – Harnessing the power of microRNAs for development of innovative diagnostic and therapeutic tools
Slide background
TAmiRNA – Helping to enhance your stability and quality of life with advanced age

TAmiRNA - microRNA biomarkers for more stability in life

our purpose: precision medicine

TAmiRNA is a biotech company specialized in the discovery and validation of microRNA biomarkers. Our mission is to provide validated diagnostic solutions to patients with serious aging-related illnesses. We aim to improve and prolong patient stability, health and quality of life with increasing age.

our technology: microRNA signatures 

We are specialized in biomarker development using blood-circulating microRNAs – evolutionary conserved regulators of gene expression and cell/tissue function. We develop diagnostic algorithms (“signatures”) based on the logic combination of microRNA levels and clinical parameters. We use this approach to provide decision support to doctors, clinical researchers and pharmaceutical companies for diagnosing disease and managing therapeutic treatment.
Our biomarker technology is minimal-invasive, fast and robust. We enable rapid decision making.

our focus: age-associated diseases

TAmiRNA is actively involved in R&D projects in osteoporosis (OP) and cardiovascular disease (CVD). OP and CVD are multi-factorial illnesses, which means that different tissues and cellular processes are involved during the onset and progression of disease. Using microRNA signatures we aim to decode the contributing disease factors on a personalized level, and to use this knowledge for better diagnosis.

our products: qPCR kits & software

osteomiRTM is a signature of serum microRNAs that is associated with bone quality. The osteomiR microRNA signature is intended to assess the risk of a first fracture in postmenopausal and type-2 diabetic women. This information enables timely interventions and can help to avoid fractures.


thrombomiRTM is a signature of plasma microRNAs that are associated with platelet function. The thrombomiR signature is intended to assess treatment response to anti-platelet therapy. This information helps to identify drug-resistant patients, optimize drug dosage and drug efficacy while reducing the risk of bleeding.

our services: (CDx) biomarker development 

TAmiRNA offers contract research services for companies in need of biomarker solutions. We collaborate with pharmaceutical companies in human and veterinary medicine, medtech companies and clinical research groups to generate tailored biomarker solutions. We supports our clients by providing one-stop-shop solutions for biomarker development and industrialization, including the discovery, validation and industrialization of biomarker candidates.